Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | PSD | A5PKW4 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466463 | 0.80 | AR (0.58) | ARMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL14979225 | 0.74 | MEN1 (0.52) | MEN1MAPTKMT2AGAAHTT | |
| SCHEMBL267666 | 0.72 | ALDH1A1 (0.70) | MEN1MAPTKMT2ASMN1; SMN2HTT | |
| SCHEMBL6988913 | 0.71 | IMPDH2 (0.56) | ARMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6465337 | 0.71 | KMT2A (0.72) | ARMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL27583119 | 0.70 | CYP1A2 (0.51) | ARMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL9666436 | 0.70 | ALDH1A1 (0.65) | MEN1MAPTKMT2ASMN1; SMN2HTT | |
| Methylamine SCHEMBL9267123 | 0.69 | MAPK1 (0.67) | MEN1MAPTKMT2ASMN1; SMN2HTT | |
| SCHEMBL5843025 | 0.69 | ALDH1A1 (0.44) | ARMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL5065616 | 0.68 | MAPT (0.52) | ARMEN1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | AR 6/4885MEN1 2050/4885MAPT 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.